Dr. Reddy's Laboratories launches Ramelteon Tablets in US market

Dr. Reddy's Laboratories announced the launch of Ramelteon Tablets, 8 mg, a therapeutically equivalent generic version of Rozerem (ramelteon, 8 mg) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

The Rozerem brand had U.S. sales of approximately $91.3 million MAT for the most recent twelve months ending in May 2019 according to IQVIA Health.

Dr. Reddy's Ramelteon Tablets, are available as 8 mg tablets in bottle count sizes of 30, 100, and 1000.

Rozerem is a trademark of Takeda Pharmaceutical Company.

Powered by Capital Market - Live News